. 2019 Aug 23;10(10):1984–1992. doi: 10.1111/1759-7714.13179

Table 3.

The clinical characteristics of patients with or without lung involvement LCH

	Characteristics		Lung involvement (n)	Without lung involvement (n)	P‐value
Children	Gender	Male	4	10	1.000
	Gender	Female	3	5	1.000
	LCH subtype	SS	0	8	0.022
	LCH subtype	MS‐RO⁺ & MS‐RO⁻	7	7	0.022
	BRAF^V600Estatus	WT	6	11	1.000
	BRAF^V600Estatus	MT	1	4	1.000
	Pituitary involvement	Yes	7	11	0.263
	Pituitary involvement	No	0	4	0.263
	Thyroid involvement	Yes	2	0	0.091
	Thyroid involvement	No	5	15	0.091
	Prognosis	Cured/improved/stable	6	15	0.318
	Prognosis	Exacerbation/relapse/died	1	0	0.318
Adults	Gender	Male	21	11	0.094
	Gender	Female	5	8	0.094
	LCH subtype	SS	4	6	0.354
	LCH subtype	MS‐RO⁺ & MS‐RO⁻	22	13	0.354
	BRAF^V600Estatus	WT	21	14	0.840
	BRAF^V600Estatus	MT	5	5	0.840
	Pituitary involvement	Yes	14	10	0.936
	Pituitary involvement	No	12	9	0.936
	Thyroid involvement	Yes	6	0	0.071
	Thyroid involvement	No	20	19	0.071
	Prognosis	Cured/improved/stable	21	18	0.359
	Prognosis	Exacerbation/relapse/died	5	1	0.359

LCH, Langerhans cell histiocytosis; MS, multisystem; RO, risk organ; SS, single system; WT, wild type.